Hepatitis C virus immunogenic compositions and methods of use thereof

US10881726B2 · kind B2 · utility

Assignees

• The Governors of the University of Alberta · CA
• Helmholtz Center for Infection Research · DE

Inventors

• Michael Houghton · Berkeley, US
• Abdolamir Landi · Edmonton, CA
• Carlos Guzman · Wolfenbüttel, DE
• Thomas Ebensen · Hannover, DE
• Darren Hockman · Edmonton, CA
• John L. Law · Edmonton, CA
• Michael Logan · Edmonton, CA

Key dates

• Filing date: Oct 5, 2017
• Grant date: Jan 5, 2021
• Expiry date: Oct 5, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2770/24234
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.